AVALO THERAPEUTICS, INC. (AVTX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
24/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinAVTX / S&P 23.78% / 15.20% |
LoseAVTX / S&P AVTX unavailable / 15.00% |
LoseAVTX / S&P 2.10% / 50.40% |
| 2026-Q10/3 |
LoseAVTX / S&P -17.79% / -4.33% |
LoseAVTX / S&P AVTX unavailable / 11.30% |
LoseAVTX / S&P -66.77% / 27.70% |
| 2025-Q41/3 |
WinAVTX / S&P 42.88% / 2.65% |
LoseAVTX / S&P AVTX unavailable / 9.00% |
LoseAVTX / S&P -96.33% / 13.40% |
| 2025-Q31/3 |
WinAVTX / S&P 154.71% / 8.12% |
LoseAVTX / S&P AVTX unavailable / 4.61% |
LoseAVTX / S&P -91.03% / 13.45% |
| 2025-Q20/3 |
LoseAVTX / S&P -37.70% / 10.94% |
LoseAVTX / S&P AVTX unavailable / 4.83% |
LoseAVTX / S&P -93.37% / 10.63% |
| 2025-Q11/3 |
WinAVTX / S&P 7.81% / -4.27% |
LoseAVTX / S&P AVTX unavailable / 4.98% |
LoseAVTX / S&P -91.41% / 10.57% |
| 2024-Q40/3 |
LoseAVTX / S&P -21.79% / 2.41% |
LoseAVTX / S&P -77.09% / 5.25% |
LoseAVTX / S&P -38.48% / 6.15% |
| 2024-Q30/3 |
LoseAVTX / S&P -23.82% / 5.89% |
LoseAVTX / S&P -63.56% / 5.89% |
LoseAVTX / S&P -97.17% / 6.11% |
| 2024-Q20/3 |
LoseAVTX / S&P -42.67% / 4.28% |
LoseAVTX / S&P -95.24% / 5.38% |
LoseAVTX / S&P -95.40% / 5.12% |
| 2024-Q11/3 |
WinAVTX / S&P 139.01% / 10.56% |
LoseAVTX / S&P -91.64% / 5.71% |
LoseAVTX / S&P -84.88% / 5.59% |
| 2023-Q40/3 |
LoseAVTX / S&P -68.66% / 11.69% |
LoseAVTX / S&P -89.34% / 6.81% |
LoseAVTX / S&P -76.10% / 7.78% |
| 2023-Q30/3 |
LoseAVTX / S&P -65.92% / -3.27% |
LoseAVTX / S&P -87.05% / 7.52% |
LoseAVTX / S&P AVTX unavailable / -5.03% |
| 2023-Q21/3 |
LoseAVTX / S&P -79.71% / 8.74% |
WinAVTX / S&P 349.35% / 9.50% |
LoseAVTX / S&P AVTX unavailable / -8.57% |
| 2023-Q11/3 |
LoseAVTX / S&P -65.28% / 7.50% |
WinAVTX / S&P 184.62% / 10.77% |
LoseAVTX / S&P AVTX unavailable / -15.69% |
| 2022-Q42/3 |
WinAVTX / S&P 51.81% / 7.56% |
WinAVTX / S&P 234.46% / 11.88% |
LoseAVTX / S&P AVTX unavailable / -17.99% |
| 2022-Q31/3 |
LoseAVTX / S&P -44.67% / -4.88% |
WinAVTX / S&P 160.28% / 13.47% |
LoseAVTX / S&P AVTX unavailable / -1.41% |
| 2022-Q20/3 |
LoseAVTX / S&P -31.03% / -16.10% |
LoseAVTX / S&P -41.35% / 13.71% |
LoseAVTX / S&P AVTX unavailable / 11.04% |
| 2022-Q11/3 |
LoseAVTX / S&P -57.35% / -4.60% |
WinAVTX / S&P 37.97% / 15.97% |
LoseAVTX / S&P AVTX unavailable / 42.23% |
| 2021-Q40/3 |
LoseAVTX / S&P -22.02% / 11.03% |
LoseAVTX / S&P -19.45% / 15.00% |
LoseAVTX / S&P AVTX unavailable / 96.40% |
| 2021-Q31/3 |
LoseAVTX / S&P -33.33% / 0.58% |
WinAVTX / S&P 15.41% / 10.77% |
LoseAVTX / S&P AVTX unavailable / 69.42% |
| 2021-Q20/3 |
LoseAVTX / S&P 8.28% / 8.55% |
LoseAVTX / S&P -6.37% / 6.58% |
LoseAVTX / S&P AVTX unavailable / 51.81% |
| 2021-Q11/3 |
WinAVTX / S&P 14.39% / 6.17% |
LoseAVTX / S&P -36.22% / -1.06% |
LoseAVTX / S&P AVTX unavailable / 7.39% |
| 2020-Q42/3 |
WinAVTX / S&P 16.04% / 12.15% |
WinAVTX / S&P -0.75% / -3.72% |
LoseAVTX / S&P AVTX unavailable / -33.42% |
| 2020-Q30/3 |
LoseAVTX / S&P -12.50% / 8.93% |
LoseAVTX / S&P -4094.95% / -2.04% |
LoseAVTX / S&P AVTX unavailable / -27.10% |
| 2020-Q21/3 |
LoseAVTX / S&P 4.84% / 20.54% |
WinAVTX / S&P 297.62% / -0.46% |
LoseAVTX / S&P AVTX unavailable / -27.11% |
| 2020-Q11/3 |
LoseAVTX / S&P -53.99% / -19.60% |
WinAVTX / S&P 35.26% / 3.47% |
LoseAVTX / S&P AVTX unavailable / -14.75% |
| 2019-Q41/3 |
WinAVTX / S&P 63.83% / 9.07% |
LoseAVTX / S&P -3.96% / 5.36% |
LoseAVTX / S&P AVTX unavailable / 2.99% |
| 2019-Q30/3 |
LoseAVTX / S&P -39.52% / 1.70% |
LoseAVTX / S&P -100.93% / 5.02% |
LoseAVTX / S&P AVTX unavailable / 0.21% |
| 2019-Q20/3 |
LoseAVTX / S&P -6.85% / 4.30% |
LoseAVTX / S&P -95.27% / 6.64% |
LoseAVTX / S&P AVTX unavailable / 8.65% |
| 2019-Q11/3 |
WinAVTX / S&P 80.80% / 13.65% |
LoseAVTX / S&P -83.95% / 8.12% |
LoseAVTX / S&P AVTX unavailable / 14.29% |
| 2018-Q40/3 |
LoseAVTX / S&P -30.84% / -13.52% |
LoseAVTX / S&P -74.38% / 9.05% |
LoseAVTX / S&P AVTX unavailable / 18.23% |
| 2018-Q30/3 |
LoseAVTX / S&P 7.60% / 7.71% |
LoseAVTX / S&P -38.62% / 10.21% |
LoseAVTX / S&P AVTX unavailable / 19.06% |
| 2018-Q21/3 |
LoseAVTX / S&P 1.17% / 3.43% |
WinAVTX / S&P 5430.50% / 9.03% |
LoseAVTX / S&P AVTX unavailable / 14.46% |
| 2018-Q11/3 |
WinAVTX / S&P 34.06% / -0.76% |
LoseAVTX / S&P AVTX unavailable / 7.68% |
LoseAVTX / S&P AVTX unavailable / 12.46% |
| 2017-Q41/3 |
WinAVTX / S&P 276.47% / 6.64% |
LoseAVTX / S&P AVTX unavailable / 7.03% |
LoseAVTX / S&P AVTX unavailable / 13.82% |
| 2017-Q31/3 |
WinAVTX / S&P 48.34% / 4.48% |
LoseAVTX / S&P AVTX unavailable / 5.68% |
LoseAVTX / S&P AVTX unavailable / 17.57% |
| 2017-Q20/3 |
LoseAVTX / S&P -15.11% / 3.09% |
LoseAVTX / S&P AVTX unavailable / 4.83% |
LoseAVTX / S&P AVTX unavailable / 17.74% |
| 2017-Q10/3 |
LoseAVTX / S&P -23.30% / 6.07% |
LoseAVTX / S&P AVTX unavailable / 3.67% |
LoseAVTX / S&P AVTX unavailable / 13.32% |
| 2016-Q40/3 |
LoseAVTX / S&P -79.20% / 3.82% |
LoseAVTX / S&P AVTX unavailable / 2.09% |
LoseAVTX / S&P AVTX unavailable / 7.05% |
| 2016-Q31/3 |
WinAVTX / S&P 92.27% / 3.85% |
LoseAVTX / S&P AVTX unavailable / 0.20% |
LoseAVTX / S&P AVTX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AVTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 115.82% | 20.78% |
| Annualized return | 115.82% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AVTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.79% | 83.14% |
| Annualized return | -70.73% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AVTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.82% | 319.30% |
| Annualized return | -46.78% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |